Mission: The Bioscience Committee advocates for the interests of the bioscience industry in the greater Baltimore region by identifying specific barriers to industry growth and finding ways to overcome them. The goal of the committee is to provide an environment where technologies from our research universities can translate into products and company formation.
Chair: This committee is chaired by David Block, MD, MBA, CEO of Gliknik. Dr. Block is a serial entrepreneur and the founder of Ruxton Pharmaceuticals and Gliknik. He has been in the bioscience industry for 17 years, 12 of which were in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals including sales management, licensing, portfolio planning, market development and product launch. He was executive vice president of International Operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002 to 2004 Dr. Block was the chief operating officer of Celera Genomics.
Members: Membership in the Bioscience Committee is by invitation only. This is to keep a constant ratio of largely company CEOs and service providers. Members include: Dr. Blake Paterson, CEO, Cerecor; Trudy Burke, Senior Manager, Baltimore Operations and Gliadel, Eisai; Marco Chacon, CEO, Paragon Bioservices; and Julie Garner, Government Affairs Manager, MedImmune.
What does the committee do:
- Actively advocates for legislation at both the state and federal level that will support the industry and help it grow. This includes annual efforts to increase the amount of the Maryland Biotech Tax Credit and working with the federal delegation to increase the percentage of funding that goes to commercial companies when SBIRs are awarded.
- Helped establish the Maryland Biotechnology Center.
- Conducted a comprehensive survey of all 400 bioscience companies in Maryland to find out how they would like to see state resources utilized.
- Created and ran the Maryland Bioscience Awards for seven years.
- Created a long-term strategy for growing the bioscience industry in Baltimore and is now writing a report on that research.
- Sponsored creation of a new business model for translational medicine.
- Worked with DBED and other industry advocates to produce regulations favorable to the industry in the administration of the Biotech Tax Credit.
What is the value in joining: The Bioscience Committee is recognized as an effective advocacy and informational resource. Through this committee, the GBC partners with other bioscience industry groups to ensure that the industry is always well represented. The committee draws its strength from the input of its members and from the strength of its voice which is directly connected to the number and caliber of companies that join. This is also an excellent way to meet other members of the bioscience business community and to interface with our research universities.
2015 Bioscience Committee news:
The Bioscience Committee has identified keeping bio startups in Baltimore and giving them the support they need to succeed as its project for the year. The committee is considering numerous initiatives to support this project, both hands-on and legislative. Among these are: commercialization as part of a tenure track in Maryland universities; educating would-be entrepreneurs among local higher education faculty; enhancing existing funding sources for startups; finding ways to provide follow on investing; working with major companies such as Johnson and Johnson for funding; creating a program similar to Dreamit but for bios only; net operating loss legislation; and working with state pension fund to carve out more investment dollars for venture funding.
February 12, 2015: Johns Hopkins Technology Ventures
By Helen Montag, senior director for corporate relations, Johns Hopkins Technology Ventures